Skip to main content

Showing 1–2 of 2 results for author: Zuber, E

Searching in archive stat. Search in all archives.
.
  1. arXiv:2310.20658  [pdf

    stat.AP

    Monitoring overall survival in pivotal trials in indolent cancers

    Authors: Thomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, Frank Bretz, Arunava Chakravartty, Thibaud Coroller, Evanthia Koukouli, Janet Wittes, Nigel Yateman, Emmanuel Zuber

    Abstract: Indolent cancers are characterized by long overall survival (OS) times. Therefore, powering a clinical trial to provide definitive assessment of the effects of an experimental intervention on OS in a reasonable timeframe is generally infeasible. Instead, the primary outcome in many pivotal trials is an intermediate clinical response such as progression-free survival (PFS). In several recently repo… ▽ More

    Submitted 4 June, 2024; v1 submitted 31 October, 2023; originally announced October 2023.

    Comments: 28 pages, 5 tables

  2. arXiv:2112.10404  [pdf, other

    stat.AP stat.ME

    The Predictive Individual Effect for Survival Data

    Authors: Beat Neuenschwander, Satrajit Roychoudhury, Simon Wandel, Kannan Natarajan, Emmanuel Zuber

    Abstract: The call for patient-focused drug development is loud and clear, as expressed in the 21st Century Cures Act and in recent guidelines and initiatives of regulatory agencies. Among the factors contributing to modernized drug development and improved health-care activities are easily interpretable measures of clinical benefit. In addition, special care is needed for cancer trials with time-to-event e… ▽ More

    Submitted 20 December, 2021; originally announced December 2021.